View Older Stories View More Recent Stories
-
Roth Capital Affirms Neuralstem (CUR) at 'Buy'; Says Rest of 2016 Will be Uneventful
-
Streetinsider.com's Hot Lunchtime Reads 11/8: (DEPO) (VRX) (VIPS) (PGNX)
-
Roth Capital Affirms Stemline Therapeutics (STML) at 'Buy'; Strong Cash Position Noted Ahead of ASH
-
Roth Capital Reaffirms TG Therapeutics (TGTX) at 'Buy'; Still Sees TGR-1202, TG-1101 as Well Positioned
-
ROTH Capital Partners to Host Innovations in Oncology Corporate Access Day in New York on November 17, 2016
-
Hannon Armstrong (HASI) Prices 3.5M Common Stock Offering for Proceeds of ~$70M
-
Hannon Armstrong Sustainable Infrastructure Capital, Inc. Announces the Pricing of its Public Offering of Common Stock
-
Hannon Armstrong Sustainable Infrastructure Capital, Inc. Announces Public Offering of Common Stock
-
Roth Capital Downgrades First Solar (FSLR) to Neutral
-
Demand Media to Participate at the ROTH Capital Partners Technology Corporate Access Day
-
Adesto Technologies to Participate at the ROTH Technology Corporate Access Day on November 16
-
Pixelworks to Participate at Upcoming Financial Conferences on November 16
-
Roth Capital Upgrades Etsy (ETSY) to Buy
-
RedHill Biopharma to Host Investor Conference Call Today at 18:00 EDT Following Announcement of Proposed Public Offering of its American Depository Shares
-
RedHill Biopharma to Host Investor Conference Call Today at 18:00 EDT Following Announcement of Proposed Public Offering of its American Depository Shares
-
RedHill Biopharma (RDHL) Plans ADS Offering
-
RedHill Biopharma Announces Proposed Public Offering of its American Depository Shares
-
RedHill Biopharma Announces Proposed Public Offering of its American Depository Shares
-
ROTH Capital Partners to Host Technology Corporate Access Day in New York City, NY on November 16th, 2016
-
Notable Analyst Rating Changes 11/1: (CVX) (TGNA) (JCI) Upgraded; (MA) (JNPR) (GDDY) Downgraded
-
Roth Capital Starts Global Blood Therapeutics (GBT) at Buy, PT $47
-
Roth Capital Starts Acushnet (GOLF) at Buy
-
eGain to Participate at the ROTH Technology Corporate Access Day on November 16, 2016
-
Roth Capital Upgrades Dynamic Materials (BOOM) to Buy
-
Streetinsider.com's Hot Lunchtime Reads 10/31: (MCD) (HOG) (CHPR) (REGN)
-
Roth Capital Confident in Full Sarilumab Approval; Affirms Regeneron (REGN) at 'Buy'
-
Quantenna Communications (QTNA) IPO Opens at $16.80/Share
-
Quantenna Communications (QTNA) Prices 6.7M Common Stock IPO at $16/Share, at Upper-End of Expected Range
-
Quantenna Communications, Inc. Announces Pricing of Initial Public Offering
-
Roth Capital Confident in Improving FY17 Visibility for Ballard Power (BLDP); Reaffirms at 'Buy'
-
Notable Analyst Rating Changes 10/27: (NOW) (AVY) (GRUB) Upgraded; (ETR) (PB) (SNI) Downgraded
-
Roth Capital Upgrades PCM, Inc (PCMI) to Buy
-
Biocept Appoints David Moskowitz Vice President, Strategy & Corporate Communications
-
Roth Capital Upgrades GrubHub Inc. (GRUB) to Buy
-
BTIG Builds Out Equity Research Group with Biotechnology Analyst Robert C. Hazlett, III
-
MeetMe's (MEET) Price Target Raised to $9.25 at Roth
-
Roth Capital Downgrades FuelCell Energy (FCEL) to Neutral on Beacon Falls Miss
-
Streetinsider.com's Hot Lunchtime Reads 10/24: (ADRO) (AMTD) (TWTR) (INO)
-
Roth Capital Affirms Bioblast Pharma (ORPN) at 'Buy'; Sees Trehalose PK Data as 'Meaningful'
-
Roth Capital Trims PT on Aduro Biotech (ADRO) to $20 Amid FDA Partial Hold on LADD Trials
-
Notable Analyst Rating Changes 10/21: (CHK) (NRF) (AVT) Upgraded; (MEMP) (YHOO) (WWAV) Downgraded
-
Northwest Biotherapeutics (NWBO) Enters $5M Common Stock Registered Direct Offering
-
NW BIO Announces Registered Direct Offering
-
Roth Capital Starts Asure Software (ASUR) at Buy
-
Roth Affirms Applied Genetic Tech (AGTC) at 'Neutral' Amid CNGA3 IND Filing; Application Expands Present Pipeline
-
Biocept Announces Closing of $10 Million Public Offering of Common Stock and Warrants
-
Ocean Power Technologies, Inc. Announces Closing of Common Stock Offering
-
Roth Capital Keeps Cerulean Pharma (CERU) at 'Buy' Amid Capital Raise, Key Collaboration with Novartis
-
Roth Capital Would be Buyers of Cree (CREE) on Turnaround; Affirms at 'Buy'
-
Roth Capital Resumes Acadia Pharmaceuticals (ACAD) at Neutral

